Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized M

Dianthus Therapeutics (Nasdaq: DNTH) said it initiated the Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis (AChR+). The global, randomized, placebo-controlled study enrolls ~195 patients; claseprubart 300mg/2mL is dosed Q2W or Q4W vs placebo. Top-line results are expected in 2H’28.

First Western Financial Inc (MYFW) reported Q3 2026 net income up 88%, but non-interest income fell $600,000. Loan growth was strong at 14%, with expectations of 10% for 2026 and 15% into 2027. ROA remains below 1%, with 1% expected in 2027. Deposit costs rose, and mortgage production declined. Management sees opportunities in trust and investment management fees.

Balchem Corp (BCPC) reported Q3 2026 record revenue of $291M, up 8.6%, with all segments growing. EBITDA rose 12.4% to $80M, marking 29 straight quarters of growth. The company faces inflationary pressures and seasonality challenges but expects year-over-year growth in Q4. Inventory increased to $177M due to inflation and growth. Clinical trials in Alzheimer's and cardiovascular health show promise, with marketing efforts planned. BCPC's effective tax rate is expected to be 22.5-23%.

Kinsale Capital Group (KNSL) reported Q3 2026 earnings with gross written premium down 4.8% and net written premium down 1.5% due to competition. Diluted EPS fell 28.4% YoY, driven by losses on fixed maturity sales. Management expects steady premiums and maintains a 20% ROE target. The company plans to continue its $100M quarterly buyback rate.

Meta Platforms (META) reported Q3 2026 revenue of $64.6B, up 26% YoY, with strong user growth and engagement. Expenses rose 68% YoY to $51.6B, including legal charges, reducing GAAP operating income by 37%. Free cash flow was negative $2.1B. Reality Labs revenue declined 6% YoY. The company launched Muse, an AI agent, and announced a 2-for-1 stock split. Meta expects significant AI investments to continue, with 2026 expenses projected at $175-179B and capital expenditures at $135-145B.